Owens & Minor (NYSE:OMI) Price Target Lowered to $14.00 at Robert W. Baird

Owens & Minor (NYSE:OMI) had its target price decreased by equities research analysts at Robert W. Baird from $19.00 to $14.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage presently has a “neutral” rating on the stock. Robert W. Baird’s target price suggests a potential upside of 16.67% from the company’s previous close.

Other equities research analysts have also issued research reports about the company. Barclays lowered their price objective on Owens & Minor from $23.00 to $18.00 and set an “equal weight” rating on the stock in a research report on Monday, August 5th. StockNews.com lowered shares of Owens & Minor from a “buy” rating to a “hold” rating in a research report on Monday, August 26th. JPMorgan Chase & Co. decreased their price objective on shares of Owens & Minor from $22.00 to $18.00 and set an “underweight” rating for the company in a research report on Wednesday, August 21st. Finally, Citigroup raised shares of Owens & Minor from a “neutral” rating to a “buy” rating and lowered their target price for the stock from $24.00 to $19.00 in a research note on Friday, July 19th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $19.29.

Owens & Minor Stock Performance

OMI opened at $12.00 on Tuesday. The company has a current ratio of 1.09, a quick ratio of 0.51 and a debt-to-equity ratio of 2.17. Owens & Minor has a 12-month low of $11.75 and a 12-month high of $28.35. The firm has a 50 day moving average of $14.62 and a two-hundred day moving average of $16.28. The firm has a market capitalization of $925.20 million, a PE ratio of -21.43, a P/E/G ratio of 0.43 and a beta of 0.41.

Owens & Minor (NYSE:OMI) last issued its earnings results on Monday, November 4th. The company reported $0.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.40 by $0.02. Owens & Minor had a negative net margin of 0.40% and a positive return on equity of 14.66%. The firm had revenue of $2.72 billion during the quarter, compared to analysts’ expectations of $2.68 billion. During the same quarter last year, the company posted $0.44 earnings per share. The firm’s revenue was up 5.0% compared to the same quarter last year. On average, analysts anticipate that Owens & Minor will post 1.57 EPS for the current year.

Institutional Trading of Owens & Minor

Large investors have recently made changes to their positions in the company. Quarry LP grew its holdings in shares of Owens & Minor by 290.1% during the second quarter. Quarry LP now owns 2,099 shares of the company’s stock worth $28,000 after buying an additional 1,561 shares in the last quarter. Innealta Capital LLC acquired a new stake in Owens & Minor in the 2nd quarter valued at about $43,000. DekaBank Deutsche Girozentrale lifted its stake in Owens & Minor by 76.6% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 3,126 shares of the company’s stock worth $43,000 after purchasing an additional 1,356 shares in the last quarter. Blue Trust Inc. boosted its holdings in shares of Owens & Minor by 176.8% during the 3rd quarter. Blue Trust Inc. now owns 2,787 shares of the company’s stock worth $44,000 after purchasing an additional 1,780 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC grew its position in shares of Owens & Minor by 100.6% in the second quarter. Allspring Global Investments Holdings LLC now owns 6,071 shares of the company’s stock valued at $82,000 after purchasing an additional 3,044 shares in the last quarter. 98.04% of the stock is currently owned by hedge funds and other institutional investors.

Owens & Minor Company Profile

Owens & Minor, Inc, together with its subsidiaries, operates as a healthcare solutions company worldwide. It operates through Products & Healthcare Services and Patient Direct segments. The Products & Healthcare Services segment offers a portfolio of products and services to healthcare providers and manufacturers.